Filled in by*

Date*

Info Sheet for Technical description

No. XXXX (事務局付番)

| Organiza | ation | | * Mandatoty fields | | | | | | |
|--|---|--|---|--|--|--|--|--|--|
| Name of C | Organization* | TWOCELLS COMPANY, LIMITED | | | | | | | |
| Address, City, States, Zip, Country* | | Hitroshima-Sangyo-Bunka Center 11F, 16-35 Hijiyama-hommachi, Minamiku, Hiroshima City, 732-0816, Japan | | | | | | | |
| URL | | https://www.twocells.com/ | | | | | | | |
| Brief Descriptions of Organization* (Approx. 100 words) | | We are developing allogeneic regenerative medical products using serum-free media developed in-house. We hold patents on large-scale culture of mesenchymal stem cells using serum-free media, adaptation to many diseases, and formulations. | | | | | | | |
| | | Name* | Masaya Matsumoto | | | | | | |
| Contact address | | Department* / Position | Director(Clinical Development) | | | | | | |
| | | E-mail* / TEL | e-mail:matsumoto-masaya@twocells.com tell:+80 082-250-3138 | | | | | | |
| What kind ☑ | d of technology do you want to offer? | * | → Please see Sheet [A] | | | | | | |
| V | B. Regenerative Medicine-related Consumables | / Instruments / Materials / CDMO Servicies etc. | → Please see Sheet (B) | | | | | | |
| | C. Platform Technologies(*) that are not included in the above (Group B) → Please see Sheet [C] | | | | | | | | |
| * Peripheral technologies that contribute to a significant the value chain of pharmaceuticals, from research ultimately market launch. | | | | | | | | | |
| The techno | ree to the following, please check "Yes ologies introduced in this 'Info Sheet' are in n research papers or have related patent ap Yes | the public domain, as they have been | | | | | | | |
| Do you have any collaborations/partnerships with pharmaceutical companies? | | | | | | | | | |
| | □ Yes | | | | | | | | |
| V | No | | | | | | | | |
| | ve already received funding from VCs of the community of | or other sources, up to which stage has | | | | | | | |
| | Angel / Seed (including AMED/JST grants) | | | | | | | | |
| | Series A | | | | | | | | |
| V | Series B | | | | | | | | |
| | Series C | | | | | | | | |
| | Series D or further advenced stages | | | | | | | | |
| Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? * | | | | | | | | | |
| | Options* | | Comments | | | | | | |
| V | Yes | | | | | | | | |
| | No | | | | | | | | |
| | | | | | | | | | |

Masaya Matumoto

7-Sep-23

Sheet (B) Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Servicies etc.

Info Sheet for Technical overview

No. XXXX(事務局付番)

| | | | | | * Mandatoty fields | | | | |
|---|---|---|--|----------|----------------------|--|--|--|--|
| Title* | | | | | | | | | |
| Regenerative medicine product development | | | | | | | | | |
| Category* | • | | | | | | | | |
| | Facilities | | Manufacturing equipment | | Inspection equipment | | | | |
| V | Cells | abla | Culture medium | | Reagents | | | | |
| Ø | Cell banking | | Storage / Container | | Logistics | | | | |
| | Cell / Viral vector manufacturing technology | | | | | | | | |
| Description* | | | | | | | | | |
| December | | | | | | | | | |
| I | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | Total Community City and a second | c | | | | | |
| | reloping regenerative medical ovide clinically usable cells (w | | and their raw materials, serum= um) and serum free media. | ree meai | a. | | | | |
| 110 00 | , , , , , , , , , , , , , , , , , , , | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | and condition to the condition | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| We can provide | e clinically usable cells and media. | | | | | | | | |
| | Filled in by* | Masaya Matsumoto | | | | | | | |
| | Date* | 7-Sep-23 | | | | | | | |